Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay

Not yet recruiting

• Conditions: SARS-CoV-2; COVID-19; RSV; Influenza

• Registration Number: NCT06689423
• Lead Sponsor: Credo Diagnostics Biomedical Pte. Ltd.

Brief Summary

The purpose of this clinical trial is to demonstrate the clinical performance of the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay in detecting SARS-CoV-2, Flu A, Flu B and RSV in symptomatic population. The primary aim is to determine the PPA/NPA against a comparator assay. The secondary aim is to determine the diagnostic sensitivity, specificity, PPV and NPV against the standard-of-care test. Each subjects will be asked to provide both nasal swab (NS) and nasopharyngeal swab (NPS) for testing purposes.

Detailed Description

The study is designed as a multisite, observational, prospective study. Subjects will be prospectively recruited from the target population, specifically individuals displaying signs and/or symptoms of respiratory tract infections. Consent for participation will be obtained prior to any eligibility confirmation or sample collection. Subsequently, both nasal swab (NS) and nasopharyngeal swab (NPS) specimens will be collected from each subject. These specimens will be tested using both the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay and the Cepheid Xpert Xpress CoV-2/Flu/RSV plus assay (comparator) to determine the Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA).

Subjects will be recruited across up to 20 sites, targeting the following intended user groups:

Trained laboratory professionals in a central laboratory setting Trained healthcare practitioners in a point-of-care (POC) setting under CLIA moderate and high complexity.

If a standard-of-care (SOC) diagnosis is available, the sensitivity, specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) will also be calculated.

Study Timeline

• Status Verified: 2024-11
• Study Start: 2024-11
• Study First Submitted: 2024-11-13
• Study First Submitted QC: 2024-11-13
• Last Update Submitted: 2024-11-13
• Study First Posted: 2024-11-14
• Last Update Posted: 2024-11-14
• Primary Completion: 2025-03
• Study Completion: 2025-04

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Subject displaying one or more of the following signs and/or symptoms of a respiratory tract infection:

  1. Fever
  2. Cough
  3. Nasal Congestion
  4. Shortness of breath
  5. Difficulty in breathing
  6. Runny nose
  7. Sore throat
  8. Muscle pain
  9. Headache
  10. Chills
  11. Nausea
  12. Diarrhoea
  13. Vomiting
  14. New loss of taste/smell

• If age 18 or over, subject is willing and capable of providing written informed consent. If under the age of 18, parent or legal guardian is willing to and capable of providing consent/assent. Assent should be obtained from minor subjects of appropriate intellectual age as defined by the IRB.

Exclusion Criteria

• Subject is unable to provide consent and assent (as appropriate) or parental/legal guardian consent permission and assent (as appropriate) cannot be obtained.
• PI determines that specimen collection represents an unacceptable risk.
• Subjects who have already been enrolled in the study previously.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PPA and NPA	In 7 days after specimen collection	PPA and NPA between the VitaSIRO solo™ SARS-CoV-2/Flu/RSV and Cepheid Xpert® Xpress CoV-2/Flu/RSV plus assay

Secondary Outcome Measures

Name	Time	Method
Comparison to SOC testing	In 7 Days after specimen collection	Evaluation of Diagnostic Performance Metrics for the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay: Sensitivity, Specificity, PPV, and NPV Using Nasal and Nasopharyngeal Swabs Compared to Standard-of-Care Diagnostics

Trial Locations

Locations (1)

Credo Diagnostics Biomedical Pte Ltd. Taiwan Branch; 🇨🇳 New Taipei City, Taiwan